PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Loxapine→

Loxapine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1977-10-2
Molecular formula
C18H18ClN3O
Molecular weight
327.8 g/mol
Drug class
Dibenzoxazepine antipsychoticdopamine and serotonin receptor antagonist
Mechanism of action
Acts as an antagonist at central dopamine and serotonin receptors, including D2 and 5-HT2A receptors. The precise mechanism responsible for clinical antipsychotic effects is not fully established.
Indications / reported uses
  • Treatment of schizophrenia with oral formulations.
  • Acute treatment of agitation associated with schizophrenia or bipolar I disorder with the inhaled formulation, where authorised.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cf83a3e-d76d-2a1f-e063-6294a90aa6bc · https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022549s000lbl.pdf

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Loxapine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Loxapine Permitted Daily Exposure (PDE) report (the Loxapine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Loxapine Occupational Exposure Limit (OEL) report (the Loxapine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.